





Review

Oxidative Phosphorylation Dysfunction Modifies the Cell Secretome

Nuria Garrido-Pérez ^{1,2,3,4,*}, Ana Vela-Sebastián ¹, Ester López-Gallardo ^{1,2,3},
Sonia Emperador ^{1,2,3}, Eldris Iglesias ^{1,2}, Patricia Meade ^{1,2,3,4}, Cecilia Jiménez-Mallebrera ^{3,5},
Julio Montoya ^{1,2,3} , M. Pilar Bayona-Bafaluy ^{1,2,3,4} and Eduardo Ruiz-Pesini ^{1,2,3,6,*} 

¹ Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, C/Miguel Servet, 177, 50013 Zaragoza, Spain; anavela55@hotmail.com (A.V.-S.); esterlop@unizar.es (E.L.-G.); seortiz@unizar.es (S.E.); eiglesia@unizar.es (E.I.); pmeade@unizar.es (P.M.); jmontoya@unizar.es (J.M.); pbayona@unizar.es (M.P.B.-B.)

² Instituto de Investigación Sanitaria (IIS) de Aragón, Av. San Juan Bosco, 13, 50009 Zaragoza, Spain

³ Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain; cjimenezm@fsjd.org

⁴ Instituto de Biocomputación y Física de Sistemas Complejos (BIFI), Universidad de Zaragoza, C/Mariano Esquillor (Edificio I + D), 50018 Zaragoza, Spain

⁵ Unidad de Patología Neuromuscular, Departamento de Neuropediatría, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu, 2, 08950 Esplugues del Llobregat, Barcelona, Spain

⁶ Fundación ARAID, Av. de Ranillas, 1-D, 50018 Zaragoza, Spain

* Correspondence: ngarrido@unizar.es (N.G.-P.); eduruiz@unizar.es (E.R.-P.)

Received: 18 March 2020; Accepted: 9 May 2020; Published: 10 May 2020



Abstract: Mitochondrial oxidative phosphorylation disorders are extremely heterogeneous conditions. Their clinical and genetic variability makes the identification of reliable and specific biomarkers very challenging. Until now, only a few studies have focused on the effect of a defective oxidative phosphorylation functioning on the cell's secretome, although it could be a promising approach for the identification and pre-selection of potential circulating biomarkers for mitochondrial diseases. Here, we review the insights obtained from secretome studies with regard to oxidative phosphorylation dysfunction, and the biomarkers that appear, so far, to be promising to identify mitochondrial diseases. We propose two new biomarkers to be taken into account in future diagnostic trials.

Keywords: oxidative phosphorylation system; mitochondrial DNA; mitochondrial diseases; secretome; biomarkers; fibroblast growth factor 21; growth differentiation factor 15; vascular endothelial growth factor; interleukine-6

1. Introduction

The secretome represents proteins that are secreted by a cell. Secretory proteins play important roles in communication between cells and, as a consequence, may coordinate and regulate biological activities [1–3]. Secretory factor-mediated signal transduction determines physiological processes such as proliferation, growth, differentiation, migration, and metabolic regulation [4]. Furthermore, because these secretory proteins are released into blood plasma, they are widely accepted to play important roles in biological responses and homeostasis of the whole body and are closely related to disease development including metabolic and neural diseases [5]. Secretome studies are at the focus of understanding physiological or pathological conditions. The identification of circulating proteins capable of being routinely used for diagnosis, prognosis, risk stratification, and therapeutic monitoring is currently of great interest [6]. Secretome analyses have been previously carried out for many

pathophysiological conditions such as hypoxia, diabetes, and anti-cancer drug treatment [7–9], but very few of these are related to mitochondrial oxidative phosphorylation (OXPHOS) system diseases.

2. Oxidative Phosphorylation System

Mitochondria play important roles in cellular energy production, metabolism, and cellular signaling [10–12]. Mitochondrial bioenergetics touch nearly every aspect of the cell. In addition to providing most of the energy, the mitochondria generate reactive oxygen species (ROS). Given the role that mitochondria play in a great number of cellular processes, it is not unsubstantiated to think that mitochondrial function and dysfunction could result in modifications of the cell secretome.

Over 1500 proteins are required for normal mitochondrial function [13,14]. Of these, only approximately 90 proteins are directly involved in the electron transport chain (ETC) and the production of adenosine triphosphate (ATP), i.e., the OXPHOS system. OXPHOS requires the transport of electrons to molecular oxygen by the mitochondrial respiratory chain which involves four multi-subunit complexes known as complexes I, II, III, and IV (CI, CII, CIII and CIV) and two mobile electron carriers, coenzyme Q (CoQ) and cytochrome *c* (Figure 1). The respiratory chain generates a transmembrane proton gradient that is channeled by complex V (also known as ATP synthase, CV) to synthesize ATP [15].




Figure 1. Oxidative phosphorylation (OXPHOS) system. OM, IMS, IM, and M code for mitochondrial outer membrane, intermembrane space, mitochondrial inner membrane, and mitochondrial matrix, respectively; ETC, electron transport chain; CI, CII, CIII, CIV, CV, and Cyt *c*, code for respiratory complexes I, II, III, IV, ATP synthase, and cytochrome *c*, respectively; Q, coenzyme Q₁₀; NADH and NAD⁺, reduced and oxidized forms of nicotinamide adenine dinucleotide; FADH₂ and FAD, reduced and oxidized forms of flavin adenine dinucleotide, H⁺, protons; e⁻, electrons; ATP, ADP, and Pi, adenosine triphosphate, adenosine diphosphate, and inorganic phosphate, respectively; H₂O, water; O₂, oxygen; ROS, reactive oxygen species. OXPHOS inhibitors: rotenone, capsaicin; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; TTFA: thenoyltrifluoroacetone; antimycin A; NaCN: sodium cyanide; hydrogen sulfide; sodium azide; oligomycin; FCCP: carbonyl cyanide 4-[trifluoromethoxy] phenylhydrazone.

Almost all of the cell's redox reactions ultimately feed electrons into the respiratory chain. CI and CII mediate the electron transfer from NADH and FADH₂, respectively, to CoQ. CIII receives electrons from reduced CoQ and funnels electrons to cytochrome *c*. CIV ends the respiratory chain by accepting electrons from cytochrome *c* and using them to fully reduce oxygen to water [15]. The mitochondrial respiratory chain is the main source of ROS, particularly by CI and CIII (Figure 1). Excessive ROS might damage lipid membranes, proteins, and nucleic acids and have a role in the pathogenesis of mitochondrial diseases [10].

Mitochondria contain their own DNA, the mitochondrial DNA (mtDNA). Human mtDNA encodes 13 structural protein subunits of the OXPHOS system, and 2 ribosomal RNAs (rRNAs) and 22 transfer RNAs (tRNAs) that are required for intra-mitochondrial protein synthesis [16,17].

Apart from the 13 proteins encoded by the mtDNA, the rest of the mitochondrial proteins are encoded by the nuclear genome. These are translated in the cytoplasm and imported into the mitochondria. The OXPHOS system assembly requires the presence of tens of different factors. Altogether, well over 100 genes govern the process of oxidative phosphorylation, and mutations in any of these genes can cause an OXPHOS defect [17,18].

3. OXPHOS Dysfunction and Disease

Defective OXPHOS function results in disease. Mitochondrial diseases are the most common form of inherited metabolic disorders [10]. The pathophysiology of mitochondrial diseases is complex and involves genetic mutations in mtDNA or nDNA. In patients with mtDNA mutations, inheritance and clinical presentation are further complicated by the presence of multiple mtDNA genomes in an individual cell, which can often lead to a mixture of mutated and wild-type genomes, called heteroplasmy. The level of heteroplasmy is crucial in determining the extent of cellular dysfunction. Conventionally, mitochondrial diseases are a consequence of a primary defect in oxidative phosphorylation, the process by which cells produce ATP [10]. To further complicate the issue, acquired conditions, e.g., exposure to chemicals, can also lead to OXPHOS dysfunction.

Mitochondrial diseases are clinically heterogeneous, can occur at any age, and can manifest with a wide range of clinical symptoms. Mitochondrial diseases can also involve any organ or tissue and characteristically involve multiple systems, typically affecting organs that are highly dependent on aerobic metabolism, and are often relentlessly progressive with high morbidity and mortality [19]. The heterogeneity in the clinical manifestation of mitochondrial diseases means that both diagnosis and management of these disorders are extremely difficult. Diagnosis often relies on genetic testing, in addition to histochemical and biochemical analysis of tissue biopsies. Establishing the molecular mechanisms that are responsible for the exceptional variability and tissue specificity of disease manifestations remains challenging [10].

In addition to the modifications in the local tissue environment, it is feasible that metabolic alterations in the tissues affected by mitochondrial dysfunction also reshape global metabolic signals at the whole-organism level. In this case, secreted molecules could influence how disease manifest in other tissues and potentially serve as biomarkers obtained from the peripheral blood [18].

4. OXPHOS Dysfunction Modifies the Protein Secretion by the Cells

Transmitochondrial cell lines called cytoplasmic hybrids, or cybrids, can be used to confidently link a phenotype to mtDNA mutations. These cells share nDNA and differ in their mtDNA. Prigione and Cortopassi [20] used cybrids of osteosarcoma 143B cells bearing mtDNA deletions and found that these deletions decreased cellular ATP production and the secretion of fibronectin (FN) and osteoprotegerin (OPG). As a positive control they included a rho zero (ρ^0) cell line, experimentally depleted of mtDNA, which showed the same results. As negative control cells, they used cells that had been cybridized with nonpathogenic mtDNAs. In the same study, CI inhibitor rotenone (Figure 1) recapitulated the decrease in ATP production as well as the inhibition of synthesis and secretion of FN and OPG, suggesting that these are all consequences of decreased energy status [20].

Other genetic manipulations that impaired the OXPHOS system, also modify the protein secretion by the cells. A knock-in mouse for mutated thymidine kinase 2 (TK2), a deoxyribonucleoside kinase required for mtDNA synthesis, showed mtDNA depletion in white adipose tissue accompanied with reduced fat accumulation. These mice also showed a severe reduction in mRNA and circulating protein levels of leptin, an adipose-derived hormone involved in the regulation of food intake and energy expenditure [21]. Mouse 3T3-L1 cells knocked down for the mitochondrial transcription factor A (TFAM), a key activator of mitochondrial transcription as well as a participant in mitochondrial

genome replication, showed a decrease in mtDNA copy number, levels of ETC subunits, CI and CIV activities, and oxygen consumption. These cells also showed a diminished expression at both mRNA and secreted protein levels of another hormone, adiponectin, that regulates glucose levels and fatty acid catabolism [22]. Adiponectin mRNA expression was also decreased in TFAM knocked down human mesenchymal stem cells (hMSCs) [23]. Mouse 3T3-L1 or adipose-tissue-derived stem cells (mASCs) that lacked the growth arrest and DNA damage-inducible proteins-interacting protein 1 (GADD45GIP1), a mitochondrial translation/assembly factor for mtDNA-encoded polypeptides, expressed lower levels of mtDNA-encoded subunits and resulted in profound impairment of OXPHOS function. The cells displayed disrupted adipocyte differentiation, accompanied by a reduced adiponectin expression [24]. Fibroblast growth factor 21 (FGF21) and angiopoietin-like 6 (ANGPTL6), were highly induced in another model of homozygous GADD45GIP1-deficient mouse embryonic fibroblasts. This group later generated adipocyte-specific GADD45GIP1-deficient mice (AdKO). Adipose tissue from AdKO mice displayed significantly reduced levels of OXPHOS subunits compared to that from the control group. Protein expression of ANGPTL6 and FGF21 was also higher in the white adipose tissue and brown adipose tissue of AdKO mice as were their levels in serum [25].

Chemical manipulation of the OXPHOS system can also affect protein secretion (Figure 1). CI inhibitor rotenone decreased adiponectin secretion in rat adipocytes and adiponectin mRNA expression in hMSCs [23,26]. Capsaicin, another CI inhibitor, decreased leptin and increased adiponectin expression in 3T3-L1 adipocytes [27]. The CIII inhibitor antimycin A reduced adiponectin mRNA levels in mouse 3T3-L1 cells [28]. Finally, the CV inhibitor oligomycin diminished adiponectin mRNA levels and secreted adiponectin in mouse 3T3-L1 cells [22,28].

Some therapeutic drugs that impair OXPHOS function are widely used in humans. This is the case for nucleoside reverse-transcriptase inhibitors (NRTIs) used against the human immunodeficiency virus (HIV) which can inhibit the mitochondrial polymerase gamma (POLG), responsible for mtDNA replication. NRTIs decreased adiponectin mRNA expression and protein secretion in mouse 3T3-L1 and 3T3-F442A cells and in primary human subcutaneous preadipocytes [29–31]. Systemic adiponectin levels were also reduced in patients under antiretroviral therapy [32]. Our group studied the effect of NRTIs on the OXPHOS system during differentiation of human adipose-derived stem cells (hASCs). The experiments showed that 2',3'-dideoxycytidine (ddC), a specific inhibitor of POLG mtDNA synthesis, reduced adipocyte differentiation and leptin secretion by hASCs-derived adipocytes and this was accompanied with significantly reduced mtDNA levels [33]. Linezolid (LIN) is a ribosomal antibiotic with effects on mitochondrial translation and OXPHOS function. In our hands, at concentrations below the steady-state peak serum concentrations [34], LIN decreased CIV activity and inhibited mitochondrial protein synthesis in hASCs. LIN also impaired differentiation of hASCs as indicated by decreased intracellular triglycerides (TGs) and secreted leptin [33]. In agreement, chloramphenicol (CAM), another mitochondrial translation inhibitor, tends to decrease the levels of secreted leptin as well [33]. These results indicate that the OXPHOS dysfunction modifies the adipokine secretion.

5. OXPHOS Dysfunction and Secretomic Studies

In view of the above-mentioned results, we analyzed the effect of LIN on the whole adipocyte secretome by a mass-spectrometry-based secretome profiling. 48 h serum-free cell culture medium was collected and processed according to [35,36]. Samples were analyzed by nano-liquid chromatography coupled with an ion-trap mass spectrometer [37]. Following this procedure, the culture and adipocyte differentiation of hASCs in the presence or absence of LIN yielded changes in thirteen secreted proteins. Surprisingly, we did not find adiponectin and leptin in the secretome analysis by mass spectrometry despite the fact that, using enzyme-linked immunosorbent assay (ELISA), we previously observed a 4- and 6-fold increase, respectively, in their culture medium levels [33]. However, leptin is mainly detected with antibody-based methods and its absence is not a rare observation for this kind of analysis [38]. We focused in four proteins not related with cytoskeleton or extracellular matrix: fatty acid-binding

protein 4 (FABP4), apolipoprotein E (APOE), plasminogen activator inhibitor 1 (PAI-1), and complement factor D (adipsin). FABP4 and APOE levels increased with normal adipocyte differentiation, but LIN partially counteracted this increase. APOE was found specifically in the cell culture medium of adipocytes and was not present in hASCs. Adipsin amount also increased during differentiation and this was potentiated by LIN. PAI-1 quantity decreased over the adipocyte differentiation, but LIN partially inhibited this drop. Fibronectin (FN) secretion was decreased after adipocyte differentiation. This reduction was somewhat mitigated when differentiation was performed in the presence of LIN [39]. FN secretion was earlier found to be decreased in cybrid cells bearing mtDNA deletions and showing a reduced ATP production [20]. The cell lines used in the two experiments (143B cells vs. adipocytes) and the proliferating or differentiating stages could explain the discrepancy between these results.

Defects in OXPHOS function may result in pathological production of ROS. Conversely, ROS overproduction can lead to OXPHOS dysfunction [40]. Meyer, et al. [41] studied the effect of ROS on human stem-cell-derived retinal pigmented epithelium (RPE) secretome. RPE samples were stressed with paraquat (PQ), an inducer of mitochondrial ROS production, and the levels of mitochondrial CI and CII subunits were decreased. The secreted proteome was quantified by mass spectrometry. Twenty-four-hour serum-free cell culture medium was processed and analyzed by nanoflow liquid-chromatography-tandem mass spectrometry analysis (nano-LC-MS/MS). They found that ROS decreased FN, complement cascade factors, and APOE secretion. Growth differentiation factor 15 (GDF15) was highly upregulated [41]. Noteworthy, FN, APOE, and several factors of the complement secretion were modified in secretome analysis under OXPHOS dysfunction conditions [39,41].

Besides the last two studies mentioned above, no other secretomic analyses related to OXPHOS dysfunction have been published so far, although studies of specific proteins secreted by the cells under several conditions affecting OXPHOS function are mentioned later.

6. Biomarkers for OXPHOS Dysfunction

Biomarkers are indicators of biologic or pathogenic processes used for disease diagnosis, for monitoring the disease progression, and for patient response to therapeutic interventions. Since diagnosis of mitochondrial disorders is challenging, the identification of easily-accessible biomarkers is of utmost importance. Because OXPHOS dysfunction has the capacity to modify the secretome, some effort has been carried out to discover secreted mitochondrial disease-specific biomarkers or regulators of secretory signals [5]. However, given the complexity of the OXPHOS diseases, it is likely that the future diagnostic tool will not rely on a single biomarker alone but a combination of many, a “biosignature”, is required [42].

In the past years, serum FGF21 and serum GDF15 have emerged as two promising diagnostic biomarkers for mitochondrial diseases [18,43–47]. They have been subsequently validated in patient cohorts [48].

7. Fibroblast Growth Factor 21

FGF21 is a member of the fibroblast growth factor superfamily. Circulating FGF21 in humans derives mainly from the liver, but is also known to be secreted by adipocytes, myocytes, and the pancreas [49]. FGF21 is a hormone-like cytokine known to play key roles in glucose and lipid metabolism and it is currently being pursued as a therapeutic drug for obesity and T2-diabetes [50]. FGF21 has been associated with anti-inflammatory properties in various tissues [51].

FGF21 has been found to be related to OXPHOS dysfunction, as it was induced in a late-onset mitochondrial myopathy mouse model, a transgenic mouse expressing a mutation in the twinkle mtDNA helicase (TWNK) [52]. Transcriptomic analysis in this model indicated that respiratory chain-deficient skeletal muscle initiated a specific pseudo-starvation response, which was associated with considerable changes in the serum amino acid, lipid, and cytokine levels [53]. Interestingly, the serum response followed closely the progression of the pathological findings in the skeletal muscle and responded to treatment; the serum amino acid profile and cytokine levels were normalized after ketogenic diet, along with the reduction in ultrastructural mitochondrial abnormalities [53,54]. Subsequently it was

confirmed that blood FGF21 levels were highly increased in patients with primary muscle-manifesting respiratory chain deficiencies, mostly those caused by pathogenic mutations in mitochondrial DNA, correlated with disease severity and respiratory chain-deficient muscle fibers [18,55]. Therefore, serum FGF21 was reported as a potential biomarker for mitochondrial diseases [18].

The increased FGF21 secretion observed in the muscles of patients suffering from mitochondrial myopathy was recapitulated *in vitro* with mitochondrial respiratory chain inhibitors. FGF21 secretion was increased in differentiated mouse C2C12 myotubes treated with an inhibitor of complex II (TTFA, thenoyltrifluoroacetone), a respiratory chain uncoupler (FCCP, carbonyl cyanide 4-[trifluoromethoxy] phenylhydrazone), or the complex IV inhibitor sodium azide in a dose-dependent manner [55] (Figure 1).

Recently, it was found that the highest induction of FGF21 response occurs in mitochondrial disorders that primarily or secondarily affect mitochondrial translation, such as direct mutations of translation machinery or mtDNA deletions leading to imbalance of mtDNA-encoded tRNAs and rRNAs but not mutations in structural respiratory chain complexes or their assembly factors [56]. mtDNA maintenance disorders, such as those caused by nuclear gene mutations in POLG, TWNK, or thymidine phosphorylase (TYMP), also caused mtDNA deletions or point mutations and induced FGF21 [57–59]. Consistent with human data, mouse models accumulating multiple mtDNA deletions in skeletal muscle [52,60], or those with a single large heteroplasmic mtDNA deletion [61], induced FGF21, clearly linking mtDNA deletions to the cytokine response [56].

8. Growth Differentiation Factor 15

GDF15 is a cytokine of the transforming growth factor β (TGF- β) superfamily, which is expressed mainly in the placenta, kidney, liver, lung, pancreas, and prostate [62–64]. Expression of GDF15 in nearly all tissues suggests its general importance in essential cellular functions [65]. It has an essential role in regulating the cellular response to stress signals and inflammation, being involved in suppression of inflammation in early pregnancy, cancer, and cardiovascular diseases. Moreover, GDF15 is expressed in the choroid plexus acting as a potent neurotrophic factor for motor and sensory neurons [64].

We identified GDF15 as a potential diagnostic biomarker for mitochondrial diseases by a gene expression study in TK2-deficient human skeletal muscles [45]. GDF15 mRNA levels were dramatically increased in muscle from patients with TK2 mutations and the protein was constitutively secreted by skeletal muscle cells.

In order to validate the feasibility of GDF15 as a serum biomarker, its concentration was measured in the serum of 17 patients with mitochondrial diseases as well as in that of 13 patients with other pediatric diseases as a control [46]. GDF15 levels were significantly increased in the serum of mitochondrial disease patients and could clearly distinguish mitochondrial disease patients from control patients. The value of GDF15 for evaluating the therapeutic efficacy of pyruvate was remarkable [46,66].

Later [47] it was found that GDF15 was significantly elevated in mitochondrial disease patients, and appeared to increase with the clinical severity of the disease. In this study, mean GDF15 levels were ranked in the following order: Leigh syndrome (LS); mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS); Kearns–Sayre syndrome (KSS); overlapping MELAS/LS; and mitochondrial encephalopathy and lactic acidosis (MELA).

9. Fibroblast Growth Factor 21 vs Growth Differentiation Factor 15

Many biomarker studies in the last few years have been focused on both FGF21 vs GDF15 simultaneously, comparing their sensitivity and specificity as mitochondrial biomarkers. They were tested in a large patient cohort with different mitochondrial defects and it was found that GDF15 showed a higher sensitivity and specificity than FGF21 [47]. We have subsequently compared circulating GDF15 and FGF21 levels in a cohort consisting exclusively of children with a diagnosis of mitochondrial disease which included patients with mutations in both mtDNA and nDNA [67]. The results indicate that GDF15 is a sensitive and specific biomarker to guide the diagnosis of this group of complex genetic

diseases. Furthermore, it was shown that the combined use of GDF15 and FGF21 was more efficient in identifying patients than either factor alone. This strategy would be useful for example to select patients for comprehensive genetic analysis, which is still expensive and not available in all centers.

Considering the above data in patients, we determined whether mitochondrial dysfunction affects GDF15 gene expression in muscle cells [67]. To this end, C2C12 myotubes were treated with antimycin A or oligomycin (CIII and CV inhibitors, respectively, Figure 1) which caused a dramatic induction of GDF15 gene expression, as well as of FGF21 gene expression. In parallel experiments, the effects of antimycin A and oligomycin were determined in human LHCN-M2 myotubes. Similar induction was observed in human LHCN-M2 myotubes under the same conditions. Previous studies have shown that ROS production was involved in the induction of FGF21 expression by experimental mitochondrial dysfunction [68]. Effectively, treatment of C2C12 myotubes with the ROS scavenger, Trolox, blunted antimycin- and oligomycin-induced FGF21 expression. In contrast, the induction of GDF15 by the mitochondrial function inhibitors was insensitive to the presence of the ROS scavenger [67]. As mentioned above, GDF15 was highly upregulated after chronic ROS in a human stem cell-derived RPE model [41], pointing to different regulatory pathways or experimental conditions acting in the two models [41,67]. However, as with FGF21 [69], it was shown that serum GDF15 does not correlate with disease severity in a large cohort of adult m.3243A>G mtDNA mutation carriers [70]. On the other hand, GDF15 seems to be more indicative of mitochondrial diseases regardless of clinical phenotype, whereas FGF21 sensitivity for mitochondrial diseases is higher when muscle manifestations are present [45]. It seems that GDF15 levels in serum are higher in mitochondrial disease patients with multisystem involvement, like MELAS or Pearson/KSS patients [47]. Likewise serum FGF21, serum GDF15 seems to be a more specific marker for mitochondrial diseases due to mitochondrial translation and mtDNA maintenance defects, as opposed to those resulting from impaired respiratory chain complex or assembly factors [71]. Similarly to FGF21, the reliability and efficacy of GDF15 as a biomarker of mitochondrial diseases remains to be tested in others patient cohorts [42].

Presently, both FGF21 and GDF15 are more sensitive and specific than currently-used clinical diagnostic markers of mitochondrial disorders such as lactate, pyruvate, creatine kinase, alanine, or organic acids [47,67,71]. However, they are yet to be incorporated into formal diagnostic pathways. It is possible that future studies will identify additional biomarkers that, together with or separately from these two, may help in the diagnosis of mitochondrial diseases.

10. Vascular Endothelial Growth Factor

Another secreted protein which is modified by OXPHOS dysfunction is VEGF. VEGF represents a family of signaling proteins involved in both vascular development and angiogenesis [72]. Increased VEGF mRNA expression, and stimulation of the angiogenic pathway, were found in paraganglioma and pheochromocytoma tumors carrying mutations in nDNA-encoded CII subunits SDHB and SDHD that result in decreased CII activity [73,74]. Similarly, increased VEGF mRNA and protein expression were found in human embryonic kidney HEK293 cells carrying mutations in the nDNA-encoded CIII subunit UQCRB with decreased OXPHOS function [75]. Human SK-Hep1 hepatoma rho⁰ cells express more VEGF mRNA and protein than parental cells with mtDNA, rho⁺ cells. Conditioned medium from these rho⁰ cells increased the formation of tube-like structures from human umbilical vein endothelial cells and new blood vessels in chorioallantoic membrane assays [76]. An inducible mtDNA-depletor mouse expressing a dominant-negative mutation in the polymerase domain of POLG, induced mtDNA depletion in various tissues. These mice showed reduced mtDNA content, reduced mitochondrial gene expression and OXPHOS enzyme activities, and increased expression of VEGF mRNA, especially in skin [77]. Cybrids obtained from mouse Lewis lung carcinoma cells, harboring a CI mutation and having an OXPHOS defect, showed increased VEGF mRNA and protein levels and higher ability to induce neoangiogenesis than those with no mtDNA mutation [78,79].

Given these previous observations, OXPHOS inhibitors were used to cause mitochondrial dysfunction and VEGF levels were analyzed (Figure 1). In accordance, *in vitro* pretreatment of human

adipose-derived stroma cells with CI or CIII inhibitors (rotenone or antimycin, respectively) increased VEGF secretion [80]. Another CI inhibitor (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP), frequently used to model Parkinson disease, also increased the number of VEGF-expressing neurons and blood vessels in the substantia nigra of parkinsonian-rendered monkeys [81]. Administration of CIV inhibitor, sodium cyanide, to human brain microvascular pericytes resulted in increased expression of VEGF, and hydrogen sulfide, another CIV inhibitor, also has proangiogenic effects [82,83]. The ATP synthase inhibitor oligomycin increased VEGF protein production in the human U-937 monocytic cell line [84]. Likewise, 4-hydroxy-2-nonenal (4-HNE), an oxidative stress inducer, increased mtDNA point mutations and reduced CIII and CIV activity and oxygen consumption in primary rheumatoid arthritis synovial fibroblasts (RASf). 4-HNE also increased RASf VEGF immunofluorescence staining and VEGF secretion. The number of tube-like structures produced by human umbilical vein endothelial cells was also increased by 4-HNE RASf-conditioned medium [85].

The above data indicates that OXPHOS dysfunction increases VEGF expression and secretion as well as pathological angiogenesis, which is a feature of many OXPHOS disorders. Therefore, VEGF might be tested as a potential biomarker for certain mitochondrial diseases.

11. Interleukin-6

IL6 is a well-known myokine [5] as well as a pro- and anti-inflammatory cytokine [86]. Changes in IL6 secretion have been observed after manipulations that compromise the OXPHOS function. MSCs obtained from atherosclerosis subjects have greater levels of mitochondrial ROS and oxidative stress than non-atherosclerosis MSCs. Atherosclerotic-MSCs display a higher reduction of mitochondrial membrane potential, mitochondrial respiration (OCR: key metric of OXPHOS), and sensitivity to electron transport chain inhibitors than nonatherosclerotic-MSCs. Atherosclerotic-MSCs have also decreased levels of CI subunit NDUF8, CII subunit SDHB, CIII subunit core 2, and CIV subunit p.MT-CO2 [87]. Despite being cultured under normoxic conditions, atherosclerotic-MSCs have increased hypoxia-inducible factor 1 α (HIF-1 α) protein levels. Given the higher abundance of HIF-1 α in atherosclerotic-MSCs, key cytokines in the MSC medium were evaluated. Atherosclerotic-MSCs secrete higher levels of IL6, C-X-C motif chemokine ligand 8 (CXCL8), and monocyte chemoattractant protein-1/C-C motif chemokine ligand 2 (CCL2) than nonatherosclerotic-MSCs in both resting and primed conditions. Moreover, CV inhibitor oligomycin-induced mitochondrial dysfunction (Figure 1) of nonatherosclerotic-MSCs leads to an increase in ROS levels and to a shift in the cytokine/chemokine secretome similar to atherosclerotic-MSCs. Of relevance, oligomycin treatment had no impact on the atherosclerotic-MSC secretome [87]. To note, when atherosclerotic-MSCs were treated with the ROS scavenger N-acetyl-l-cysteine and measured key cytokines and chemokines of the MSC secretome, the levels of IL6, CXCL8, and CCL2, were diminished, and the atherosclerotic-MSCs survival and immunopotency were enhanced [87]. Furthermore, the mitochondria-targeted ROS scavengers, Trolox, MitoCP, and MitoTempo similarly improved the atherosclerotic-MSCs immunomodulatory capacity. Therefore, it seems that the impaired mitochondrial function of atherosclerotic-MSCs underlies their altered secretome and reduced immunopotency.

In a Kupffer-cell model of trauma-hemorrhage, the ATP levels were decreased and this was accompanied by a decline in TFAM and mtDNA-encoded p.MT-CO1 from CIV [88]. Also, IL6 and TNF- α production capacities were increased following trauma-hemorrhage. Administration of 17 β -estradiol following trauma-hemorrhage increased ATP levels and normalized Tfam, MT-CO1 mRNA and p.MT-CO1 levels as well as IL6 and TNF- α production capacity. These results suggest that 17 β -estradiol-upregulated ATP production and improved OXPHOS function in Kupffer cells leads to downregulation of cytokine release following trauma-hemorrhage.

In other experiments carried out, C57BL/6J (B6)-mice-derived Lewis lung carcinoma rho⁰ P29 cells were cybridized with mtDNA from senescence-accelerated mice P1 carrying the m.11181A>G mutation in the MT-ND4 gene. These cybrids overproduce ROS, and, when co-cultured with dendritic cells from B6 mice, induced IL6 secretion was observed from B6 cells [89]. Moreover, mutations in

POLG gene (A467T and W748S) in Alpers disease patients lead to a fatal brain and liver mitochondrial depletion syndrome with reduced activity of respiratory chain enzyme complexes [90]. Later it was observed that Alpers patients have elevated IL6, CXCL8, and IFN- γ levels in cerebrospinal fluid [91]. The above studies indicate that IL6 secretion increases along with mitochondrial OXPHOS dysfunction so IL6 could be tested as a potential biomarker for mitochondrial diseases.

12. Biosignatures

FGF21, GDF15, as well as VEGF and IL6, have been associated individually with a range of non-mitochondrial diseases, encompassing cancer, obesity, renal disease, diabetes, and liver disease, although many of them are characterized by an OXPHOS dysfunction [92,93]. Additionally, serum FGF21 is variably increased in non-mitochondrial myopathies [56,94].

Moreover, the commonly-observed co-regulation of secretome proteins, as demonstrated above, is not only observed in the context of mitochondrial dysfunction. Parallel changes for secreted FGF21, GDF15, VEGF, and IL6 proteins have been demonstrated under several physiological or pathological conditions. In a study to evaluate FGF21 as a marker of mitochondrial dysfunction in the context of acute-on-chronic liver failure, FGF21 levels and IL6 were found increased in peripheral blood samples of the patients [95]. Moreover, FGF21 and IL6 serum levels were higher in patients with ulcerative colitis and irritable bowel syndrome [96] and significantly elevated in patients with severe compared with mild acute pancreatitis [97]. Levels of GDF15 and IL6 have been found increased in acute heart failure patients [98], the two proteins were also increased in anemic T2 diabetes (T2D) patients compared with non-anemic T2D patients [99]. Finally, positive correlation was demonstrated between GDF15 and IL6 in patients suffering from early stages of chronic kidney disease [100]. Secretome proteins may also be coordinately regulated in response to environmental factors such as temperature and hazardous substances. For many years, the IL6 has been known to be secreted in response to cold environment and in response to noradrenaline in mouse brown adipocytes in primary culture [101]. Similarly, GDF15 is intensely secreted by brown fat upon exposure to cold and brown adipocytes after noradrenergic stimulation in mice [102,103]. Recently, FGF21 and IL6 were both found induced in a mouse model of cold-induced thermogenesis [104]. IL6, FGF21, and GDF15 levels were also elevated in patients with myocardial infarction treated with therapeutic hypothermia [105]. Finally, it was shown that nickel can induce the production of IL6 [106–108] as well as several other secreted signaling proteins including GDF15 and VEGF in keratocytes [109].

As these biomarkers seem to behave in a correlative manner in several disease and environmental conditions, we propose that their combination as a “biosignature” for mitochondrial diseases warrants further investigation (Figure 2).




Figure 2. Cells or tissues affected by an OXPHOS dysfunction may modify their secretome, sending signaling molecules to other organs through the bloodstream and affecting their function. Such molecules could be detected and used as biomarkers for mitochondrial diseases.

13. Conclusions

Heterogeneity is a well-recognized feature of virtually all parameters associated with OXPHOS diseases. Some metabolites firmly established in the clinical investigation of mitochondrial diseases, such as lactate, have a poor diagnostic sensitivity and specificity [48]. Recent developments in this field point at FGF21 and GDF15 as more sensitive and specific than currently-used clinical diagnostic markers, but this needs to be confirmed in other and large patient cohorts before being incorporated into routine diagnostic trials. Moreover, several secreted proteins together would increase their value further and be adequate to define a mitochondrial disease fingerprint. None of the markers discussed here is a specific biomarker of OXPHOS disease. However, given the ease of their determination in blood, the levels of these secreted proteins could be useful, together with other clinical clues, to determine if a suspected patient should proceed to a more invasive procedure, such as a muscle biopsy, to study histochemical and biochemical markers of OXPHOS disease [110]. In addition, the determination of the secreted protein levels could be useful in patients already diagnosed with an OXPHOS disease to predict their prognosis and response to treatment [48]. Although the secretion of several proteins is modified in response to OXPHOS dysfunction there are no reports on the secretome of patients with OXPHOS diseases. Therefore, secretome studies on patients with confirmed OXPHOS disease are warranted. These studies should include patients with non-OXPHOS diseases with major involvement of the muscle and/or nervous system, the most affected tissues in mitochondrial diseases. Moreover, different technical approaches must be considered in order to increase the number of proteins whose secretion is modified upon OXPHOS dysfunction.

Author Contributions: Conceptualization: N.G.-P., E.R.-P., and M.P.B.-B.; writing of the manuscript: N.G.-P., E.R.-P., and M.P.B.-B., critical review: M.P.B.-B., C.J.-M., J.M., and E.R.-P., investigation: A.V.-S., E.L.-G., S.E., E.I., and P.M., project administration, funding acquisition, supervision, writing—original draft: N.G.-P., C.J.-M., J.M., M.P.B.-B., and E.R.-P. All authors have read and agreed to the published version of the manuscript.

Acknowledgments: We would like to thank Santiago Morales for his assistance with figures. This work was supported by grants from Instituto de Salud Carlos III [FIS-PI17/00021 and PI17/00166]; Fundación Mutua Madrileña MMA17/01; Precipita-FECYT crowdfunding program (PR194); Gobierno de Aragón (Grupos Consolidados B33_17R) and FEDER 2014-2020 “Construyendo Europa desde Aragón”; Asociación de Enfermos de Patología Mitochondrial (AEPMI); Plan Nacional de I + D + I, and Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de la Investigación Sanitaria, project PI19/0122 and co-funded with European Regional Development Fund (ERDF) “A way to achieve Europe”. The CIBERER is an initiative of the ISCIII.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kapur, S.K.; Katz, A.J. Review of the adipose derived stem cell secretome. *Biochimie* **2013**, *95*, 2222–2228. [[CrossRef](#)]
2. Lehr, S.; Hartwig, S.; Lamers, D.; Famulla, S.; Müller, S.; Hanisch, F.G.; Cuvelier, C.; Ruige, J.; Eckardt, K.; Ouwens, D.M.; et al. Identification and validation of novel adipokines released from primary human adipocytes. *Mol. Cell. Proteomics* **2012**, *11*, M111.010504. [[CrossRef](#)] [[PubMed](#)]
3. Stastna, M.; Van Eyk, J.E. Secreted proteins as a fundamental source for biomarker discovery. *Proteomics* **2012**, *12*, 722–735. [[CrossRef](#)] [[PubMed](#)]
4. Farhan, H.; Rabouille, C. Signalling to and from the secretory pathway. *J. Cell Sci.* **2011**, *124*, 171–180. [[CrossRef](#)] [[PubMed](#)]
5. Song, P.; Kwon, Y.; Joo, J.Y.; Kim, D.G.; Yoon, J.H. Secretomics to discover regulators in diseases. *Int. J. Mol. Sci.* **2019**, *20*, 3893. [[CrossRef](#)] [[PubMed](#)]
6. Anjo, S.I.; Manadas, B. A translational view of cells’ secretome analysis - from untargeted proteomics to potential circulating biomarkers. *Biochimie* **2018**, *155*, 37–49. [[CrossRef](#)] [[PubMed](#)]
7. Shin, J.; Kim, G.; Kabir, M.H.; Park, S.J.; Lee, S.T.; Lee, C. Use of composite protein database including search result sequences for mass spectrometric analysis of cell secretome. *PLoS ONE* **2015**, *10*, e0121692. [[CrossRef](#)]

8. Shin, J.; Rhim, J.; Kwon, Y.; Choi, S.Y.; Shin, S.; Ha, C.W.; Lee, C. Comparative analysis of differentially secreted proteins in serum-free and serum-containing media by using BONCAT and pulsed SILAC. *Sci. Rep.* **2019**, *9*, 1–12. [[CrossRef](#)]
9. Adhikari, S.; Chen, L.; Huang, P.; Tian, R. Proteomic analysis of secreted proteins from cell microenvironment. In *Methods in Molecular Biology*; Humana Press: New York, NY, USA, 2017; Volume 1662, pp. 45–58.
10. Gorman, G.S.; Chinnery, P.F.; DiMauro, S.; Hirano, M.; Koga, Y.; McFarland, R.; Suomalainen, A.; Thorburn, D.R.; Zeviani, M.; Turnbull, D.M. Mitochondrial diseases. *Nat. Rev. Dis. Prim.* **2016**, *2*, 1–22. [[CrossRef](#)]
11. Munnich, A.; Rotig, A.; Cormier-Daire, V.; Rustin, P. Clinical Presentation of Respiratory Chain Deficiency Arnold Munnich. In *The Online Metabolic and Molecular Bases of Inherited Disease*; Valle, D.L., Antonarakis, S., Ballabio, A., Beaudet, A.L., Mitchell, G.A., Eds.; MacGraw Hill: New York, NY, USA, 2006.
12. Schoffner, J. Oxidative Phosphorylation Diseases. In *The Online Metabolic and Molecular Bases of Inherited Disease*; MacGraw Hill: New York, NY, USA, 2006.
13. Pagliarini, D.J.; Calvo, S.E.; Chang, B.; Sheth, S.A.; Scott, B.; Ong, S.; Walford, G.A.; Sugiana, C.; Boneh, A.; William, K.; et al. A mitochondrial protein compendium elucidates complex I disease biology. *Cell* **2008**, *134*, 112–123. [[CrossRef](#)]
14. Calvo, S.E.; Mootha, V.K. The Mitochondrial Proteome and Human Disease. *Annu. Rev. Genomics Hum. Genet.* **2017**, *176*, 139–148. [[CrossRef](#)] [[PubMed](#)]
15. Vafai, S.B.; Mootha, V.K. Mitochondrial disorders as windows into an ancient organelle. *Nature* **2012**, *491*, 374–383. [[CrossRef](#)] [[PubMed](#)]
16. Anderson, S.; Bankier, A.T.; Barrell, B.G.; De Bruijn, M.H.L.; Coulson, A.R.; Drouin, J.; Eperon, I.C.; Nierlich, D.P.; Roe, B.A.; Sanger, F.; et al. Sequence and organization of the human mitochondrial genome. *Nature* **1981**, *290*, 457–465. [[CrossRef](#)] [[PubMed](#)]
17. Andrews, R.M.; Kubacka, I.; Chinnery, P.F.; Lightowlers, R.N.; Turnbull, D.M.; Howell, N. Reanalysis and revision of the cambridge reference sequence for human mitochondrial DNA. *Nat. Genet.* **1999**, *23*, 147. [[CrossRef](#)]
18. Suomalainen, A. Biomarkers for mitochondrial respiratory chain disorders. *J. Inherit. Metab. Dis.* **2011**, *34*, 277–282. [[CrossRef](#)]
19. McFarland, R.; Taylor, R.W.; Turnbull, D.M. A neurological perspective on mitochondrial disease. *Lancet Neurol.* **2010**, *9*, 829–840. [[CrossRef](#)]
20. Prigione, A.; Cortopassi, G. Mitochondrial DNA deletions induce the adenosine monophosphate-activated protein kinase energy stress pathway and result in decreased secretion of some proteins. *Aging Cell* **2007**, *6*, 619–630. [[CrossRef](#)]
21. Villarroya, J.; Dorado, B.; Vilà, M.R.; Garcia-Arumí, E.; Domingo, P.; Giral, M.; Hirano, M.; Villarroya, F. Thymidine kinase 2 deficiency-induced mitochondrial dna depletion causes abnormal development of adipose tissues and adipokine levels in mice. *PLoS ONE* **2011**, *6*, e29691. [[CrossRef](#)]
22. Wang, C.H.; Wang, C.C.; Huang, H.C.; Wei, Y.H. Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes. *FEBS J.* **2013**, *280*, 1039–1050. [[CrossRef](#)]
23. Zhang, Y.; Marsboom, G.; Toth, P.T.; Rehman, J. Mitochondrial respiration regulates adipogenic differentiation of human mesenchymal stem cells. *PLoS ONE* **2013**, *8*, e77077. [[CrossRef](#)]
24. Ryu, M.J.; Kim, S.J.; Choi, M.J.; Kim, Y.K.; Lee, M.J.; Lee, S.E.; Chung, H.K.; Jung, S.B.; Kim, H.-J.; Kim, K.S.; et al. Mitochondrial oxidative phosphorylation reserve is required for hormone- and PPAR γ agonist-induced adipogenesis. *Mol. Cells* **2013**, *35*, 134–141. [[CrossRef](#)] [[PubMed](#)]
25. Kang, S.G.; Yi, H.S.; Choi, M.J.; Ryu, M.J.; Jung, S.; Chung, H.K.; Chang, J.Y.; Kim, Y.K.; Lee, S.E.; Kim, H.W.; et al. ANGPTL6 expression is coupled with mitochondrial OXPHOS function to regulate adipose FGF21. *J. Endocrinol.* **2017**, *233*, 105–118. [[CrossRef](#)] [[PubMed](#)]
26. Szkudelski, T.; Nogowski, L.; Szkudelska, K. Short-term regulation of adiponectin secretion in rat adipocytes. *Physiol. Res.* **2011**, *60*, 521–530. [[CrossRef](#)] [[PubMed](#)]
27. Hsu, C.L.; Yen, G.C. Effects of capsaicin on induction of apoptosis and inhibition of adipogenesis in 3T3-L1 cells. *J. Agric. Food Chem.* **2007**, *55*, 1730–1736. [[CrossRef](#)]
28. Chevillotte, E.; Giral, M.; Miroux, B.; Ricquier, D.; Villarroya, F. Uncoupling protein-2 controls adiponectin gene expression in adipose tissue through the modulation of reactive oxygen species production. *Diabetes* **2007**, *56*, 1042–1050. [[CrossRef](#)]

29. Stankov, M.; Lücke, T.; Das, A.; Schmidt, R.; Behrens, G.; HIV/AIDS, G.C.N. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. *Antivir. Ther.* **2007**, *12*, 205–216.
30. Stankov, M.V.; Schmidt, R.E.; Behrens, G.M.N. Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion. *Antimicrob. Agents Chemother.* **2008**, *52*, 2882–2889. [[CrossRef](#)]
31. Stankov, M.V.; Lücke, T.; Das, A.M.; Schmidt, R.E.; Behrens, G.M.N. Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors. *Antimicrob. Agents Chemother.* **2010**, *54*, 280–287. [[CrossRef](#)]
32. Hammond, E.; McKinnon, E.; Nolan, D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipotrophy: Prevalence and metabolic consequences. *Clin. Infect. Dis.* **2010**, *51*, 591–599. [[CrossRef](#)]
33. Llobet, L.; Toivonen, J.M.; Montoya, J.; Ruiz-Pesini, E.; López-Gallardo, E. Xenobiotics that affect oxidative phosphorylation alter differentiation of human adipose-derived stem cells at concentrations that are found in human blood. *Dis. Model. Mech.* **2015**, *8*, 1441–1455. [[CrossRef](#)]
34. Dryden, M.S. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. *J. Antimicrob. Chemother.* **2011**, *66*, 7–15. [[CrossRef](#)] [[PubMed](#)]
35. Merrill, M.H.; Fleisher, M.S. Factors involved in the use of organic solvents as precipitating and drying agents of immune sera. *J. Gen. Physiol.* **1932**, *16*, 243–256. [[CrossRef](#)] [[PubMed](#)]
36. Frazier, T.P.; Gimble, J.M.; Khetterpal, I.; Rowan, B.G. Impact of low oxygen on the secretome of human adipose-derived stromal/stem cell primary cultures. *Biochimie* **2013**, *95*, 2286–2296. [[CrossRef](#)] [[PubMed](#)]
37. Reales-Calderon, J.A.; Corona, F.; Monteoliva, L.; Gil, C.; Martinez, J.L. Quantitative proteomics unravels that the post-transcriptional regulator Crc modulates the generation of vesicles and secreted virulence determinants of *Pseudomonas aeruginosa*. *J. Proteom.* **2015**, *127*, 352–364. [[CrossRef](#)] [[PubMed](#)]
38. Zvonic, S.; Lefevre, M.; Kilroy, G.; Floyd, Z.E.; DeLany, J.P.; Khetterpal, I.; Gravois, A.; Dow, R.; White, A.; Wu, X.; et al. Secretome of primary cultures of human adipose-derived stem cells: Modulation of serpins by adipogenesis. *Mol. Cell. Proteomics* **2007**, *6*, 18–28. [[CrossRef](#)]
39. Llobet, L.; Bayona-Bafaluy, M.P.; Pacheu-Grau, D.; Torres-Pérez, E.; Arbones-Mainar, J.M.; Navarro, M.Á.; Gómez-Díaz, C.; Montoya, J.; López-Gallardo, E.; Ruiz-Pesini, E. Pharmacologic concentrations of linezolid modify oxidative phosphorylation function and adipocyte secretome. *Redox Biol.* **2017**, *13*, 244–254. [[CrossRef](#)]
40. Passarelli, C.; Tozzi, G.; Pastore, A.; Bertini, E.; Piemonte, F. GSSG-mediated Complex I defect in isolated cardiac mitochondria. *Int. J. Mol. Med.* **2010**, *25*, 95–99.
41. Meyer, J.G.; Garcia, T.Y.; Schilling, B.; Gibson, B.W.; Lamba, D.A. proteome and secretome dynamics of human retinal pigment epithelium in response to reactive oxygen species. *Sci. Rep.* **2019**, *9*, 1–12. [[CrossRef](#)]
42. Boenzi, S.; Diodato, D. Biomarkers for mitochondrial energy metabolism diseases. *Essays Biochem.* **2018**, *62*, 443–454.
43. Kajiyama, M.; Kawamura, I.; Fujita, A.; Hamamoto, K.; Nishi, Y.; Kitano, A.; Matsuda, I.; Ohtani, Y.; Miike, T. A case of mitochondrial encephalomyopathy with cardiomyopathy due to decreased complex I and IV activities. *Brain Dev.* **1989**, *21*, 369–373.
44. Davis, R.L.; Liang, C.; Edema-Hildebrand, F.; Riley, C.; Needham, M.; Sue, C.M. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. *Neurology* **2013**, *81*, 1819–1826. [[CrossRef](#)] [[PubMed](#)]
45. Kalko, S.G.; Paco, S.; Jou, C.; Rodríguez, M.A.; Meznaric, M.; Rogac, M.; Jekovec-Vrhovsek, M.; Sciacco, M.; Moggio, M.; Fagiolari, G.; et al. Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. *BMC Genom.* **2014**, *15*, 91. [[CrossRef](#)] [[PubMed](#)]
46. Fujita, Y.; Ito, M.; Kojima, T.; Yatsuga, S.; Koga, Y.; Tanaka, M. GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. *Mitochondrion* **2015**, *20*, 34–42. [[CrossRef](#)] [[PubMed](#)]
47. Yatsuga, S.; Fujita, Y.; Ishii, A.; Fukumoto, Y.; Arahata, H.; Kakuma, T.; Kojima, T.; Ito, M.; Tanaka, M.; Saiki, R.; et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. *Ann. Neurol.* **2015**, *78*, 814–823. [[CrossRef](#)]
48. Steele, H.E.; Horvath, R.; Lyon, J.J.; Chinnery, P.F. Monitoring clinical progression with mitochondrial disease biomarkers. *Brain* **2017**, *140*, 2530–2540. [[CrossRef](#)]
49. Morovat, A.; Weerasinghe, G.; Nesbitt, V.; Hofer, M.; Agnew, T.; Quaghebeur, G.; Sergeant, K.; Fratter, C.; Guha, N.; Mirzazadeh, M.; et al. Use of FGF-21 as a biomarker of mitochondrial disease in clinical practice. *J. Clin. Med.* **2017**, *6*, 80. [[CrossRef](#)]

50. Fisher, F.M.; Maratos-Flier, E. Understanding the Physiology of FGF21. *Annu. Rev. Physiol.* **2016**, *78*, 223–241. [[CrossRef](#)]
51. Fisher, F.F.; Kleiner, S.; Douris, N.; Fox, E.C.; Mepani, R.J.; Verdeguer, F.; Wu, J.; Kharitonov, A.; Flier, J.S.; Maratos-Flier, E.; et al. FGF21 regulates PGC-1 α and browning of white adipose tissues in adaptive thermogenesis. *Genes Dev.* **2012**, *26*, 271–281. [[CrossRef](#)]
52. Tyynismaa, H.; Peltola-Mjösund, K.; Wanrooij, S.; Lappalainen, I.; Ylikallio, E.; Jalanko, A.; Spelbrink, J.N.; Paetau, A.; Suomalainen, A. Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 17687–17692. [[CrossRef](#)]
53. Tyynismaa, H.; Carroll, C.J.; Raimundo, N.; Ahola-erkkilä, S.; Wenz, T.; Ruhanen, H.; Guse, K.; Hemminki, A.; Peltola-Mjösund, K.E.; Tulkki, V.; et al. Mitochondrial myopathy induces a starvation-like response. *Hum. Mol. Genet.* **2010**, *19*, 3948–3958. [[CrossRef](#)]
54. Ahola-Erkki, S.; Carroll, C.J.; Peltola-Mjösund, K.; Tulkki, V.; Mattila, I.; Seppänen-Laakso, T.; Orešič, M.; Tyynismaa, H.; Suomalainen, A. Ketogenic diet slows down mitochondrial myopathy progression in mice. *Hum. Mol. Genet.* **2010**, *19*, 1974–1984. [[CrossRef](#)] [[PubMed](#)]
55. Crooks, D.R.; Natarajan, T.G.; Jeong, S.Y.; Chen, C.; Park, S.Y.; Huang, H.; Ghosh, M.C.; Tong, W.H.; Haller, R.G.; Wu, C.; et al. Elevated FGF21 secretion, PGC-1 α and ketogenic enzyme expression are hallmarks of iron-sulfur cluster depletion in human skeletal muscle. *Hum. Mol. Genet.* **2014**, *23*, 24–39. [[CrossRef](#)] [[PubMed](#)]
56. Lehtonen, J.M.; Forsström, S.; Bottani, E.; Viscomi, C.; Baris, O.R.; Isoniemi, H.; Höckerstedt, K.; Österlund, P.; Hurme, M.; Jylhävä, J.; et al. FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders. *Neurology* **2016**, *87*, 2290–2299. [[CrossRef](#)] [[PubMed](#)]
57. Hudson, G.; Chinnery, P.F. Mitochondrial DNA polymerase- γ and human disease. *Hum. Mol. Genet.* **2006**, *15*, 244–252. [[CrossRef](#)]
58. Spelbrink, J.N.; Li, F.Y.; Tiranti, V.; Nikali, K.; Yuan, Q.P.; Tariq, M.; Wanrooij, S.; Garrido, N.; Comi, G.; Morandi, L.; et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria (Nature Genetics (2001) 28 (223-231)). *Nat. Genet.* **2001**, *29*, 100.
59. Nishino, I.; Spinazzola, A.; Hirano, M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. *Science* **1999**, *283*, 689–692. [[CrossRef](#)]
60. Baris, O.R.; Ederer, S.; Neuhaus, J.F.G.; von Kleist-Retzow, J.C.; Wunderlich, C.M.; Pal, M.; Wunderlich, F.T.; Peeva, V.; Zsurka, G.; Kunz, W.S.; et al. Mosaic deficiency in mitochondrial oxidative metabolism promotes cardiac arrhythmia during aging. *Cell Metab.* **2015**, *21*, 667–677. [[CrossRef](#)]
61. Inoue, K.; Nakada, K.; Hayashi, J.; Isobe, K. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. *Nat. Genet.* **2000**, *46*, 829–837. [[CrossRef](#)]
62. Zimmers, T.A.; Jin, X.; Hsiao, E.C.; McGrath, S.A.; Esquela, A.F.; Koniaris, L.G. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. *Shock* **2005**, *23*, 543–548.
63. Zimmers, T.A.; Jin, X.; Hsiao, E.C.; Perez, E.A.; Pierce, R.H.; Chavin, K.D.; Koniaris, L.G. Growth differentiation factor-15: Induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. *J. Surg. Res.* **2006**, *130*, 45–51. [[CrossRef](#)]
64. Strelau, J.; Böttner, M.; Lingor, P.; Suter-Crazzolara, C.; Galter, D.; Jaszai, J.; Sullivan, A.; Schober, A.; Krieglstein, K.; Unsicker, K. GDF-15/MIC-1 a novel member of the TGF-beta superfamily. *J. Neural Transm.* **2000**, *60*, 273–276.
65. Unsicker, K.; Björn, S.; Krieglstein, K. The multiple facets of the TGF-B family cytokine growth/differentiation factor-15/ macrophage inhibitory cytokine-1. *Cytokine Growth Factor Rev.* **2013**, *24*, 373–384. [[CrossRef](#)] [[PubMed](#)]
66. Koga, Y.; Povalko, N.; Inoue, E.; Nashiki, K.; Tanaka, M. Biomarkers and clinical rating scales for sodium pyruvate therapy in patients with mitochondrial disease. *Mitochondrion* **2019**, *48*, 11–18. [[CrossRef](#)] [[PubMed](#)]
67. Montero, R.; Yubero, D.; Villarroja, J.; Henares, D.; Jou, C.; Rodríguez, M.A.; Ramos, F.; Nascimento, A.; Ortez, C.I.; Campistol, J.; et al. GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. *PLoS ONE* **2016**, *11*, 1–15. [[CrossRef](#)]
68. Ribas, F.; Villarroja, J.; Elayne, H.; Giralt, M.; Villarroja, F. FGF21 expression and release in muscle cells: Involvement of MyoD and regulation by mitochondria-driven signalling. *Biochem. J.* **2014**, *463*, 191–199. [[CrossRef](#)]
69. Koene, S.; De Laat, P.; Van Tienoven, D.H.; Vriens, D.; Brandt, A.M.; Sweep, F.C.G.J.; Rodenburg, R.J.T.; Donders, A.R.T.; Janssen, M.C.H.; Smeitink, J.A.M. Serum FGF21 levels in adult m.3243A>G carriers: Clinical implications. *Neurology* **2014**, *83*, 125–133. [[CrossRef](#)]

70. Koene, S.; de Laat, P.; van Tienoven, D.H.; Weijers, G.; Vriens, D.; Sweep, F.C.; Timmermans, J.; Kapusta, L.; Janssen, M.C.; Smeitink, J.A. Serum GDF15 levels correlate to mitochondrial disease severity and myocardial strain, but not to disease progression in adult m.3243A>G carriers. *JIMD Rep.* **2015**, *24*, 69–81.
71. Davis, R.L.; Liang, C.; Sue, C.M. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. *Neurology* **2016**, *86*, 2010–2015. [[CrossRef](#)]
72. Holmes, K.; Roberts, O.L.; Thomas, A.M.; Cross, M.J. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. *Cell. Signal.* **2007**, *19*, 2003–2012. [[CrossRef](#)]
73. Gimenez-Roqueplo, A.P.; Favier, J.; Rustin, P.; Mourad, J.J.; Plouin, P.F.; Corvol, P.; Rötig, A.; Jeunemaitre, X. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. *Am. J. Hum. Genet.* **2001**, *69*, 1186–1197. [[CrossRef](#)]
74. Gimenez-Roqueplo, A.P.; Favier, J.; Rustin, P.; Rieubland, C.; Kerlan, V.; Plouin, P.F.; Rötig, A.; Jeunemaitre, X. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. *J. Clin. Endocrinol. Metab.* **2002**, *87*, 4771–4774. [[CrossRef](#)] [[PubMed](#)]
75. Chang, J.; Jung, H.J.; Jeong, S.H.; Kim, H.K.; Han, J.; Kwon, H.J. A mutation in the mitochondrial protein UQCRB promotes angiogenesis through the generation of mitochondrial reactive oxygen species. *Biochem. Biophys. Res. Commun.* **2014**, *455*, 290–297. [[CrossRef](#)] [[PubMed](#)]
76. Cheon, H.; Moon, H.-E.; Lee, M.-S.; Kim, S.-S. Loss of mitochondrial DNA enhances angiogenic and invasive potential of hepatoma cells. *Oncol. Rep.* **2010**, *23*, 779–786. [[PubMed](#)]
77. Singh, B.; Schoeb, T.R.; Bajpai, P.; Slominski, A.; Singh, K.K. Reversing wrinkled skin and hair loss in mice by restoring mitochondrial function. *Cell Death Dis.* **2018**, *9*, 1–14. [[CrossRef](#)]
78. Koshikawa, N.; Iyozumi, A.; Gassmann, M.; Takenaga, K. Constitutive upregulation of hypoxia-inducible factor-1 α mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. *Oncogene* **2003**, *22*, 6717–6724. [[CrossRef](#)]
79. Ishikawa, K.; Takenaga, K.; Akimoto, M.; Koshikawa, N.; Yamaguchi, A.; Imanishi, H.; Nakada, K.; Honma, Y.; Hayashi, J.-I. ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis. *Science* **2008**, *320*, 661–664. [[CrossRef](#)]
80. Carrière, A.; Ebrahimian, T.G.; Dehez, S.; Augé, N.; Joffre, C.; André, M.; Arnal, S.; Duriez, M.; Barreau, C.; Arnaud, E.; et al. Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy. *Arterioscler. Thromb. Vasc. Biol.* **2009**, *29*, 1093–1099. [[CrossRef](#)]
81. Barcia, C.; Bautista, V.; Sánchez-Bahillo, Á.; Fernández-Villalba, E.; Faucheux, B.; Poza, Y.; Poza, M.; Fernandez Barreiro, A.; Hirsch, E.C.; Herrero, M.T. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. *J. Neural Transm.* **2005**, *112*, 1237–1248. [[CrossRef](#)]
82. Bai, Y.; Zhu, X.; Chao, J.; Zhang, Y.; Qian, C.; Li, P.; Liu, D.; Han, B.; Zhao, L.; Zhang, J.; et al. Pericytes contribute to the disruption of the cerebral endothelial barrier via increasing VEGF expression: Implications for stroke. *PLoS ONE* **2015**, *10*, 1–20. [[CrossRef](#)]
83. Longchamp, A.; Mirabella, T.; Arduini, A.; MacArthur, M.R.; Das, A.; Treviño-Villarreal, J.H.; Hine, C.; Ben-Sahra, I.; Knudsen, N.H.; Brace, L.E.; et al. Amino acid restriction triggers angiogenesis via GCN2/ATF4 regulation of VEGF and H2S production. *Cell* **2018**, *173*, 117–129. [[CrossRef](#)]
84. Satake, S.; Kuzuya, M.; Miura, H.; Asai, T.; Ramos, M.A.; Muraguchi, M.; Ohmoto, Y.; Iguchi, A. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. *Biol. Cell* **1998**, *90*, 161–168. [[CrossRef](#)]
85. Balogh, E.; Veale, D.J.; McGarry, T.; Orr, C.; Szekanecz, Z.; Ng, C.T.; Fearon, U.; Biniiecka, M. Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis. *Arthritis Res. Ther.* **2018**, *20*, 1–15. [[CrossRef](#)] [[PubMed](#)]
86. Rose-John, S. Interleukin-6 family cytokines. *Cold Spring Harb. Perspect. Biol.* **2018**, *10*, 1–18. [[CrossRef](#)] [[PubMed](#)]
87. Mancini, O.K.; Lora, M.; Cuillerier, A.; Shum-Tim, D.; Hamdy, R.; Burelle, Y.; Servant, M.J.; Stochaj, U.; Colmegna, I. Mitochondrial oxidative stress reduces the immunopotency of mesenchymal stromal cells in adults with coronary artery disease. *Circ. Res.* **2018**, *122*, 255–266. [[CrossRef](#)]
88. Hsieh, Y.-C.; Frink, M.; Kawasaki, T.; Thobe, B.M.; Choudhry, M.A.; Schwacha, M.G.; Bland, K.I.; Chaudry, I.H. Downregulation of TLR4-dependent ATP production is critical for estrogen-mediated immunoprotection in Kupffer cells following trauma-hemorrhage. *J. Cell. Physiol.* **2007**, *211*, 364–370. [[CrossRef](#)]

89. Imanishi, H.; Takibuchi, G.; Kobayashi, T.; Ishikawa, K.; Nakada, K.; Mori, M.; Kikkawa, Y.; Takenaga, K.; Toyama-Sorimachi, N.; Hayashi, J.I. Specific mtDNA mutations in mouse carcinoma cells suppress their tumor formation via activation of the host innate immune system. *PLoS ONE* **2013**, *8*, 1–10. [[CrossRef](#)]
90. Nguyen, K.V.; Sharief, F.S.; Chan, S.S.L.; Copeland, W.C.; Naviaux, R.K. Molecular diagnosis of Alpers syndrome. *J. Hepatol.* **2006**, *45*, 108–116. [[CrossRef](#)]
91. Hasselmann, O.; Blau, N.; Ramaekers, V.T.; Quadros, E.V.; Sequeira, J.M.; Weissert, M. Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. *Mol. Genet. Metab.* **2010**, *99*, 58–61. [[CrossRef](#)]
92. Semba, R.D.; Sun, K.; Egan, J.M.; Crasto, C.; Carlson, O.D.; Ferrucci, L. Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: The Baltimore longitudinal study of aging. *J. Clin. Endocrinol. Metab.* **2012**, *97*, 1375–1382. [[CrossRef](#)]
93. Chow, W.S.; Xu, A.; Woo, Y.C.; Tso, A.W.K.; Cheung, S.C.W.; Fong, C.H.Y.; Tse, H.F.; Chau, M.T.; Cheung, B.M.Y.; Lam, K.S.L. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. *Arterioscler. Thromb. Vasc. Biol.* **2013**, *33*, 2454–2459. [[CrossRef](#)]
94. Lovadi, E.; Csereklyei, M.; Merkli, H.; Fülöp, K.; Sebők, Á.; Karcagi, V.; Komoly, S.; Pál, E. Elevated FGF 21 in myotonic dystrophy type 1 and mitochondrial diseases. *Muscle Nerve* **2017**, *55*, 564–569. [[CrossRef](#)] [[PubMed](#)]
95. Ruiz-Margáin, A.; Pohlmann, A.; Ryan, P.; Schierwagen, R.; Chi-Cervera, L.A.; Jansen, C.; Mendez-Guerrero, O.; Flores-García, N.C.; Lehmann, J.; Torre, A.; et al. Fibroblast growth factor 21 is an early predictor of acute-on-chronic liver failure in critically ill cirrhotic patients. *Liver Transplant.* **2018**, *24*, 595–605. [[CrossRef](#)] [[PubMed](#)]
96. Moraes, L.; Magnusson, M.K.; Mavroudis, G.; Polster, A.; Jonefjäll, B.; Törnblom, H.; Sundin, J.; Simrén, M.; Strid, H.; Öhman, L. Systemic inflammatory protein profiles distinguish irritable bowel syndrome (IBS) and ulcerative colitis, irrespective of inflammation or IBS-like symptoms. *Inflamm. Bowel Dis.* **2020**, 1–11. [[CrossRef](#)] [[PubMed](#)]
97. Novotny, D.; Malina, P.; Krumpholcova, P.; Tozzi, I. Total adiponectin, adipocyte fatty acid binding protein, fibroblast growth factor 21 and proinflammatory marker levels during the early stage of acute pancreatitis. *Clin. Lab.* **2015**, *61*, 1119–1128. [[CrossRef](#)] [[PubMed](#)]
98. Boulogne, M.; Sadoune, M.; Launay, J.M.; Baudet, M.; Cohen-Solal, A.; Logeart, D. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. *Int. J. Cardiol.* **2017**, *226*, 53–59. [[CrossRef](#)] [[PubMed](#)]
99. Hong, J.H.; Choi, Y.K.; Min, B.K.; Park, K.S.; Seong, K.; Lee, I.K.; Kim, J.G. Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment. *Diabetes Res. Clin. Pract.* **2015**, *109*, 64–70. [[CrossRef](#)] [[PubMed](#)]
100. Lukaszzyk, E.; Lukaszzyk, M.; Koc-Zorawska, E.; Bodzenta-Lukaszzyk, A.; Malyszko, J. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients. *Int. Urol. Nephrol.* **2016**, *48*, 839–844. [[CrossRef](#)]
101. Buryšek, L.; Houštěk, J. β -Adrenergic stimulation of interleukin-1 α and interleukin-6 expression in mouse brown adipocytes. *FEBS Lett.* **1997**, *411*, 83–86. [[CrossRef](#)]
102. Verdeguer, F.; Soustek, M.S.; Hatting, M.; Blättler, S.M.; McDonald, D.; Barrow, J.J.; Puigserver, P. Brown Adipose YY1 Deficiency Activates Expression of Secreted Proteins Linked to Energy Expenditure and Prevents Diet-Induced Obesity. *Mol. Cell. Biol.* **2015**, *36*, 184–196. [[CrossRef](#)]
103. Campderrós, L.; Moure, R.; Cairó, M.; Gavaldà-Navarro, A.; Quesada-López, T.; Cereijo, R.; Giralt, M.; Villarroya, J.; Villarroya, F. Brown adipocytes secrete GDF15 in response to thermogenic activation. *Obesity* **2019**, *27*, 1606–1616. [[CrossRef](#)]
104. Bal, N.C.; Maurya, S.K.; Pani, S.; Sethy, C.; Banerjee, A.; Das, S.; Patnaik, S.; Kundu, C.N. Mild cold induced thermogenesis: Are BAT and skeletal muscle synergistic partners? *Biosci. Rep.* **2017**, *37*, 1–11. [[CrossRef](#)] [[PubMed](#)]
105. Mohammad, M.A.; Noc, M.; Lang, I.; Holzer, M.; Clemmensen, P.; Jensen, U.; Metzler, B.; Erlinge, D. Proteomics in hypothermia as adjunctive therapy in patients with ST-segment elevation myocardial infarction: A CHILL-MI substudy. *Ther. Hypothermia Temp. Manag.* **2017**, *7*, 152–161. [[CrossRef](#)] [[PubMed](#)]
106. Oxholm, A.; Oxholm, P.; Avnstorp, C.; Bendtzen, K. Keratinocyte-expression of interleukin-6 but not of tumour necrosis factor-alpha is increased in the allergic and the irritant patch test reaction. *Acta Derm Venereol.* **1991**, *71*, 93–98. [[PubMed](#)]
107. Guéniche, A.; Viac, J.; Lizard, G.; Charveron, M.; Schmitt, D. Effect of nickel on the activation state of normal human keratinocytes through interleukin 1 and intercellular adhesion molecule 1 expression. *Br. J. Dermatol.* **1994**, *131*, 250–256. [[CrossRef](#)]

108. Lisby, S.; Müller, K.M.; Jongeneel, C.V.; Saurat, J.H.; Hauser, C. Nickel and skin irritants up-regulate tumor necrosis factor- α mRNA in keratinocytes by different but potentially synergistic mechanisms. *Int. Immunol.* **1995**, *7*, 343–352. [[CrossRef](#)]
109. Gazel, A.; Rosdy, M.; Tornier, C.; De Fraissinette, A.D.B.; Blumenberg, M. Transcriptional profiling defines the effects of nickel in human epidermal keratinocytes. *J. Cell. Physiol.* **2008**, *217*, 686–692. [[CrossRef](#)]
110. Muraresku, C.C.; McCormick, E.M.; Falk, M.J. Mitochondrial disease: Advances in clinical diagnosis, management, therapeutic development, and preventative strategies. *Curr. Genet. Med. Rep.* **2018**, *6*, 62–72. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).